{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:39:54Z","timestamp":1789497594652,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Epidemiology of prolactin-secreting pituitary neuroendocrine tumours (PRL-PitNETs) remains scarce and inconsistent. It is a heterogeneous disease regarding age at onset, sex, and tumour characteristics. We aimed to assess temporal epidemiological trends in PRL-PitNETs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cohort study, systematic review, and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cohort study comprised all PRL-PitNET patients in the North Denmark Region (2017-2022; N = 594 634), identified via ICD-10 coding (E22.1) or dopamine agonist treatment. Data included sex, age at diagnosis, adenoma size, and prolactin levels. For the systematic review, PubMed and Embase were searched (May 2025) for studies reporting \u226520 PRL-PitNETs. Extracted data comprised prevalence, incidence, age, and sex distributions. A random-effects meta-analysis was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 245 patients: 167 microprolactinomas, 78 macroprolactinomas, and 20 incidentalomas. From 2017 to 2022, prevalence increased by 41% (95% CI: 25%-60%, +61 cases) overall, 42% (95% CI: 19%-68%, +39 cases) for microprolactinomas, 41% (95% CI: 19%-67%, +22 cases) for macroprolactinomas, and 57% (95% CI: 6%-132%, +7 cases) for incidentalomas. Overall incidence was 2.8 (95% CI: 2.2-3.5) per 100 000 person-years. The systematic review and meta-analysis (15 studies, 16 000 PRL-PitNET cases) showed an increasing PRL-PitNET prevalence and incidence, reaching 41 (95% PI: 12-89) per 100 000 persons and 2.3 (95% PI: 1.2-4.3) per 100 000 person-years, respectively; with a phenotypical shift towards more men (from 10%-20% to 20%-30%), macroprolactinomas (\u223c25 to \u223c30%) and incidentalomas (\u223c6% to \u223c10%) over the last two decades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PRL-PitNETs are increasingly prevalent, partly driven by a rising incidence of men and incidentalomas, suggesting a phenotypic shift and associated increase in clinical and healthcare burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf254","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:34:57Z","timestamp":1765802097000},"page":"745-761","source":"Crossref","is-referenced-by-count":1,"title":["Rising burden of PRL-PitNETs: patterns across tumour sizes and incidentalomas"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5627-598X","authenticated-orcid":false,"given":"Frederik \u00d8stergaard","family":"Klit","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Aalborg University Hospital , 9000 Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9260 Gistrup ,","place":["Denmark"]},{"name":"Steno Diabetes Center North Denmark , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Faartoft","family":"N\u00f8rg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aalborg University Hospital , 9000 Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Sofie Dam","family":"Berrett","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aalborg University Hospital , 9000 Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-4387","authenticated-orcid":false,"given":"Christian","family":"Rosendal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aalborg University Hospital , 9000 Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Nikontovic","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center North Denmark , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aalborg University Hospital , 9000 Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9260 Gistrup ,","place":["Denmark"]},{"name":"Steno Diabetes Center North Denmark , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-6724","authenticated-orcid":false,"given":"Jesper","family":"Krogh","sequence":"additional","affiliation":[{"name":"Clinic for Pituitary Disorders, Department of Medicine, Zealand University Hospital Koge , 4600 Koge ,","place":["Denmark"]},{"name":"Institute of Clinical Medicine, University of Copenhagen , 2200 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-3413","authenticated-orcid":false,"given":"Kirstine","family":"Stochholm","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Dal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aalborg University Hospital , 9000 Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aalborg University , 9260 Gistrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"2","key":"2026010202520850500_lvaf254-B1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026010202520850500_lvaf254-B2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2026010202520850500_lvaf254-B3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1530\/EC-17-0171","article-title":"Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study","volume":"6","author":"Soto-Pedre","year":"2017","journal-title":"Endocr Connect"},{"issue":"2","key":"2026010202520850500_lvaf254-B4","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026010202520850500_lvaf254-B5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/ph16010122","article-title":"Prolactin relationship with fertility and in vitro fertilization outcomes\u2014a review of the literature","volume":"16","author":"Iancu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"12","key":"2026010202520850500_lvaf254-B6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"6)","key":"2026010202520850500_lvaf254-B7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s11102-024-01421-z","article-title":"Impact of medical therapy for hormone-secreting pituitary tumors on bone","volume":"27","author":"Freda","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026010202520850500_lvaf254-B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11102-024-01392-1","article-title":"Quality of life in prolactinoma: a systematic review","volume":"27","author":"Castle-Kirszbaum","year":"2024","journal-title":"Pituitary"},{"issue":"06","key":"2026010202520850500_lvaf254-B9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0043-107243","article-title":"Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality","volume":"49","author":"Krogh","year":"2017","journal-title":"Horm Metab Res"},{"issue":"1","key":"2026010202520850500_lvaf254-B10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/cen.13498","article-title":"Males with prolactinoma are at increased risk of incident cardiovascular disease","volume":"88","author":"Toulis","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2026010202520850500_lvaf254-B11","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"Raappana","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2026010202520850500_lvaf254-B12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3803\/EnM.2021.1000","article-title":"Descriptive epidemiology and survival analysis of prolactinomas and Cushing's disease in Korea","volume":"36","author":"Park","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"2","key":"2026010202520850500_lvaf254-B13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5144\/0256-4947.2020.105","article-title":"Prevalence and characteristics of sellar masses in the city of Al Ain, United Arab Emirates: 2011 to 2016","volume":"40","author":"Aldahmani","year":"2020","journal-title":"Ann Saudi Med"},{"issue":"6","key":"2026010202520850500_lvaf254-B14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1590\/2359-3997000000195","article-title":"Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a health management organization in Buenos Aires, Argentina","volume":"60","author":"Day","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"12","key":"2026010202520850500_lvaf254-B15","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Li\u00e8ge, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2026010202520850500_lvaf254-B16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026010202520850500_lvaf254-B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-020-01084-6","article-title":"Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study","volume":"24","author":"Oh","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"2026010202520850500_lvaf254-B18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011","volume":"171","author":"Tj\u00f6rnstrand","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026010202520850500_lvaf254-B19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026010202520850500_lvaf254-B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1017\/cjn.2015.301","article-title":"Sellar masses: an epidemiological study","volume":"43","author":"Al-Dahmani","year":"2016","journal-title":"Can J Neurol Sci."},{"issue":"4","key":"2026010202520850500_lvaf254-B21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11154-024-09875-z","article-title":"The changing landscape of acromegaly\u2014an epidemiological perspective","volume":"25","author":"Rosendal","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2026010202520850500_lvaf254-B22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/cen.14828","article-title":"The prevalence of acromegaly is higher than previously reported: changes over a three-decade period","volume":"97","author":"Aagaard","year":"2022","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2026010202520850500_lvaf254-B23","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2026010202520850500_lvaf254-B24","doi-asserted-by":"publisher","first-page":"e00010","DOI":"10.3389\/fendo.2019.00010","article-title":"Clinical relevance of genetic analysis in patients with pituitary adenomas: a systematic review","volume":"10","author":"van den Broek","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2026010202520850500_lvaf254-B25","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2026010202520850500_lvaf254-B26","author":"Danish Regions"},{"key":"2026010202520850500_lvaf254-B27","author":"North Denmark Region"},{"key":"2026010202520850500_lvaf254-B28","author":"Statistics Denmark"},{"key":"2026010202520850500_lvaf254-B29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"2","key":"2026010202520850500_lvaf254-B30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immbio.2007.02.001","article-title":"Une alternative \u00e0 la chromatographie pour la d\u00e9tection de la macroprolactine\u202f: calcul du rapport de deux immunodosages de la prolactine\u202f: immulite 2000\u00ae et Kryptor\u00ae","volume":"22","author":"Rojat","year":"2007","journal-title":"Immuno-Analyse et Biologie Specialisee"},{"issue":"3","key":"2026010202520850500_lvaf254-B31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.immbio.2005.03.001","article-title":"Dosages de prolactine Elecsys\u00ae et Kryptor\u00ae et macroprolactine","volume":"20","author":"Sapin","year":"2005","journal-title":"Immuno-Analyse et Biologie Specialisee"},{"key":"2026010202520850500_lvaf254-B32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026010202520850500_lvaf254-B33","author":"Statistics Sweden"},{"key":"2026010202520850500_lvaf254-B34","author":"Statistics Iceland"},{"issue":"2","key":"2026010202520850500_lvaf254-B35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/cen.13064","article-title":"Epidemiology and radiological geometric assessment of pituitary macroadenomas: population-based study","volume":"85","author":"Gruppetta","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026010202520850500_lvaf254-B36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"Gruppetta","year":"2013","journal-title":"Pituitary"},{"issue":"3","key":"2026010202520850500_lvaf254-B37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"2026010202520850500_lvaf254-B38","author":"Ahmad","year":"2001"},{"key":"2026010202520850500_lvaf254-B39","author":"National Cancer Institute"},{"issue":"223","key":"2026010202520850500_lvaf254-B40","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.53738\/revmed.2009.5.223.2172","article-title":"Epid\u00e9miologie des ad\u00e9nomes hypophysaires: Etude dans une agglom\u00e9ration urbaine de Suisse","volume":"5","author":"Fontana","year":"2009","journal-title":"Rev Med Suisse"},{"issue":"1","key":"2026010202520850500_lvaf254-B41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cen.13156","article-title":"The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the prolactin epidemiology, audit and research study (PROLEARS)","volume":"86","author":"Soto-Pedre","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026010202520850500_lvaf254-B42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2026010202520850500_lvaf254-B43","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1210\/jcem.82.7.4088","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study*","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026010202520850500_lvaf254-B44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","article-title":"Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference","volume":"57","author":"Kreutz","year":"2015","journal-title":"Neuroradiology"},{"issue":"4","key":"2026010202520850500_lvaf254-B45","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf254\/65944510\/lvaf254.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/6\/745\/65944510\/lvaf254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/6\/745\/65944510\/lvaf254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:52:13Z","timestamp":1767340333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/6\/745\/8382688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf254","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,26]]}}}